QUINOLINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASE Axl/Mer AND CSF1R Russian patent published in 2024 - IPC C07D401/12 C07D401/14 C07D405/14 C07D409/14 C07D413/14 A61K31/4709 A61K31/501 A61K45/00 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound having the general formula I, where X¹ is independently in each case selected from CR³ and N; X² is independently selected from CR⁴ and N in each case; n is independently selected from 0 and 1 in each case; and independently in each case selected from any structure given in the following group W; R¹ is independently in each case selected from the group consisting of hydrogen, C1-C6 alkyl, -(C=O)R⁵; R² represents -OR⁸; R³ and R⁴ are independently in each case selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, C1-C4 haloalkyl; R⁵ and R⁶ are independently in each case selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl; R⁸ is independently in each case a C1-C4 haloalkyl; Z¹ in each case is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with one of OR⁵ and NR⁵R⁶, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl containing 1 heteroatom, selected from O and N; R¹¹ and R¹² are independently in each case selected from the group consisting of C1-C6 alkyl, C1-C4 haloalkyl, and pharmacologically acceptable salts thereof. The invention also relates to a pharmaceutical composition based on the said compound.

EFFECT: obtaining of a new compound and a pharmaceutical composition based on it to be used in medicine for the treatment of disorders mediated by the receptor tyrosine kinase Axl/Mer and CSF1R, namely for the treatment of myeloid leukemia, breast cancer and non-small cell lung cancer.

19 cl, 8 tbl, 8 ex, 2 dwg